Table 2.
Indications | Age ≤12 yr |
Age 12–18 yr |
Total |
---|---|---|---|
Count (%) | Count (%) | ||
Variceal surviellance/Eradication | 58 (36.9) | 99 (63.1) | 157 |
Suspected CLD | 31 (33.7) | 61 (66.3) | 92 |
EHPVO | 18 (40) | 27 (60) | 45 |
Check EGD | 9 (45) | 11 (55) | 20 |
Dyspepsia | 29 (20.3) | 114 (79.7) | 143 |
UGI bleeding | 40 (29.4) | 96 (70.6) | 136 |
Abdominal pain | 48 (51.1) | 46 (48.9) | 94 |
Anemia | 35 (47.3) | 39 (52.7) | 74 |
Vomiting | 20 (40) | 30 (60) | 50 |
GERD | 16 (44.4) | 18 (55.6) | 34 |
MAS | 15 (53.6) | 13 (46.4) | 28 |
Biliary ascariasis | 1 (5.9) | 16 (94.1) | 17 |
Dysphagia | 8 (47.1) | 9 (52.9) | 17 |
Acute pancreatitis | 2 (20) | 8 (80) | 10 |
Corrosive injury | 2 (20) | 8 (80) | 10 |
Hematochezia | 2 (20) | 8 (80) | 10 |
Others | 2 (9.1) | 40 (95.2) | 42 |
Total | 278 (33.8) | 544 (66.2) | 822 |
CLD, chronic liver disease; EGD, esophagogastroduodenoscopy; EHPVO, extrahepatic portal venous obstruction; GERD, gastroesophageal reflux disease; MAS, malabsorption syndrome; UGI, upper gastrointestinal.